Eliem Therapeutics, Inc. (ELYM)
NASDAQ: ELYM · IEX Real-Time Price · USD
8.25
+0.07 (0.86%)
May 17, 2024, 4:00 PM EDT - Market closed
Company Description
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.
The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Eliem Therapeutics, Inc.
Country | United States |
Founded | 2018 |
IPO Date | Aug 10, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Dr. Andrew Levin M.D., Ph.D. |
Contact Details
Address: 2801 Centerville Road 1st Floor, Pmb #117 Wilmington, Delaware 19808 United States | |
Phone | 877-354-3689 |
Website | eliemtx.com |
Stock Details
Ticker Symbol | ELYM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $12.50 |
CIK Code | 0001768446 |
CUSIP Number | 28658R106 |
ISIN Number | US28658R1068 |
Employer ID | 83-2273741 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Andrew Levin M.D., Ph.D. | Principal Financial Officer and Executive Chairman |
Dr. Valerie Morisset Ph.D. | Chief Scientific Officer and Executive Vice President of Research and Development |
Emily Pimblett | Principal Accounting Officer |
Jo Palmer-Phillips Ph.D. | Chief Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 17, 2024 | PREM14A | Filing |
May 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
May 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
May 15, 2024 | 10-Q | Quarterly Report |
May 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Apr 29, 2024 | 10-K/A | [Amend] Annual report |
Apr 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 11, 2024 | 8-K | Current Report |
Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |